GO:0090327 negative regulation of locomotion involved in locomotory behavior

Locomotion is a fundamental behavioral output that allows organisms to forage, escape predators, and respond to environmental cues. The Gene Ontology term GO:0090327, negative regulation of locomotion involved in locomotory behavior, captures the biological processes that decrease the frequency, rate, or extent of self-propelled movement in a behavioral context. This term is distinct from general locomotion regulation because it specifically addresses the behavioral dimension of movement suppression, such as stopping, slowing, or pausing during exploration. Understanding this process is critical for neurobiology, ethology, and translational research because dysregulated movement control underlies multiple neurological and psychiatric conditions. At the molecular level, negative regulation of locomotion involves neuromodulatory signals, second messenger cascades, and motor neuron excitability changes. In Caenorhabditis elegans, activation of RHO-1 in cholinergic motor neurons competes with dopamine signaling to control locomotion, providing a genetically tractable model for dissecting this process. Similarly, Luqin-like RYamide peptides regulate food-evoked responses, demonstrating how neuropeptidergic signaling can suppress or gate locomotory behavior. These findings establish that negative regulation of locomotion is not a passive absence of movement but an actively regulated behavioral state. For researchers, GO:0090327 provides a standardized framework to annotate genes and pathways that suppress locomotion. By integrating genetic, pharmacological, and behavioral data, this term helps link molecular mechanisms to organismal behavior. It also offers a conceptual bridge between cell-autonomous signaling, such as RAF-AKT crosstalk observed in hybrid cells, and circuit-level control of movement. This article reviews the definition, mechanisms, key genes, disease relevance, and CRISPR-based research methods for GO:0090327.

GO:0090327 is defined as any process that decreases the frequency, rate, or extent of the self-propelled movement of a cell or organism from one location to another in a behavioral context; it specifically refers to the aspect of locomotory behavior having to do with movement. In simpler terms, it is the active suppression or slowing of movement as part of an animal's behavioral repertoire, rather than a defect in the motor machinery itself.

Negative regulation of locomotion involved in locomotory behavior is important because it governs when and how organisms pause, stop, or slow down, which is essential for survival, energy conservation, and appropriate responses to sensory cues. Disruptions in this process can lead to hyperactivity, impulsivity, or abnormal movement patterns seen in neurological and psychiatric disorders. Moreover, understanding the molecular brakes on locomotion can inform therapeutic strategies for conditions characterized by excessive or inappropriate movement.

The following genes and proteins have been implicated in negative regulation of locomotion involved in locomotory behavior or related signaling pathways.

Negative regulation of locomotion involved in locomotory behavior is regulated by competing neuromodulatory inputs, particularly dopamine and RHO-1 signaling in cholinergic motor neurons. Neuropeptides such as Luqin-like RYamide peptides modulate food-evoked responses, providing another layer of control. Additionally, intracellular RAF-AKT crosstalk can rewire signaling to influence cell behavior, which may extend to neuronal regulation of movement.

Disruptions in negative regulation of locomotion can contribute to movement disorders characterized by excessive or inappropriate motor activity. Dopamine signaling, which opposes RHO-1 to suppress locomotion, is a well-known target in Parkinson's disease and related conditions. Understanding how RHO-1 and dopamine compete may reveal new therapeutic entry points for modulating movement.

Although GO:0090327 primarily describes organismal behavior, the underlying signaling pathways overlap with those controlling cell migration. Hybrid cells derived from breast epithelial and cancer cell fusion events show differential RAF-AKT crosstalk, suggesting that similar molecular switches could influence metastatic spread. Targeting these pathways may help suppress cancer cell motility.

Luqin-like RYamide peptides regulate food-evoked responses in C. elegans, linking negative regulation of locomotion to feeding behavior and energy balance. Dysregulation of such neuropeptidergic signaling could contribute to eating disorders or obesity-related movement changes.

Quantitative behavioral tracking in C. elegans allows measurement of speed, pause frequency, and reversal rate, which are direct readouts of negative regulation of locomotion. These assays can be combined with genetic perturbations to test causality.

CRISPR knockout, point mutation, knock-in, and overexpression enable precise testing of candidate genes in locomotion circuits. For example, RHO-1 activation can be manipulated to assess its competition with dopamine signaling.

Biochemical and imaging approaches can measure RAF-AKT crosstalk and second messenger dynamics in hybrid cells or neurons. These methods help link molecular changes to behavioral outcomes.

Quantification of Luqin-like RYamide peptides and dopamine levels provides insight into neuromodulatory control of locomotion. Such profiling can be paired with receptor knockout to dissect circuit mechanisms.

Researchers studying negative regulation of locomotion involved in locomotory behavior-related genes often need to determine whether a candidate gene is causally involved in movement suppression or simply correlated with behavioral changes. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models for such functional studies.

GO:0090327, negative regulation of locomotion involved in locomotory behavior, is a biologically_process term that captures the active suppression of movement in behavioral contexts. Research in C. elegans has identified key roles for RHO-1, dopamine signaling, and Luqin-like RYamide peptides in this process. Additionally, RAF-AKT crosstalk in hybrid cells highlights broader signaling principles that may apply to locomotion control. Understanding these mechanisms has implications for neurological disorders and cancer metastasis. By leveraging CRISPR-based models and behavioral assays, researchers can causally test candidate genes and uncover new regulators of locomotion suppression. EDITGENE offers comprehensive services to accelerate such discoveries, from knockout and knock-in models to library screening and bioinformatics support.